Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOGAT2 | Q3SYC2 | 12/20 | 0.46 |
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | XPO1 | O14980 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21636539 | 0.81 | MOGAT2 (0.32) | MOGAT2ARPGR | |
| SCHEMBL21624113 | 0.80 | MOGAT2 (0.40) | MOGAT2PGR | |
| SCHEMBL21624006 | 0.73 | MOGAT2 (0.43) | MOGAT2ARPGR | |
| SCHEMBL21636543 | 0.73 | MEN1 (0.34) | MOGAT2ALDH1A1MAPTHPGDALOX15 | |
| SCHEMBL21624172 | 0.69 | AKR1B1 (0.43) | POLB | |
| SCHEMBL23658699 | 0.68 | MOGAT2 (0.31) | MOGAT2 | |
| SCHEMBL21624022 | 0.68 | TGM2 (0.41) | MOGAT2PGR | |
| SCHEMBL4898502 | 0.68 | KIF11 (0.50) | MOGAT2ARNOTUM | |
| SCHEMBL21624183 | 0.68 | CES1 (0.45) | MOGAT2ARPGRALDH1A1HPGD | |
| SCHEMBL24767506 | 0.68 | MOGAT2 (0.39) | MOGAT2ARPGRNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139488-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünethal GmbH (DE) | 2021-05-13 | — | — | US | disclosed |
| WO-2020016453-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139488-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | NR3C1, NR3C2, GRK5 | MOGAT2 3787/4885AR 505/4885PGR 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.